Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021

被引：104

作者：

Harder, Thomas ^{[1
]}

Kuelper-Schiek, Wiebe ^{[1
]}

Reda, Sarah ^{[1
]}

Treskova-Schwarzbach, Marina ^{[1
]}

Koch, Judith ^{[1
]}

Vygen-Bonnet, Sabine ^{[1
]}

Wichmann, Ole ^{[1
]}

机构：

[1] Robert Koch Inst, Berlin, Germany

来源：

EUROSURVEILLANCE | 2021年 / 26卷 / 41期

关键词：

D O I：

10.2807/1560-7917.ES.2021.26.41.2100920

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9-76.9) against asymptomatic infection, 75.7% (95% CI: 69.3-80.8) against symptomatic infection and 90.9% (95% CI: 84.5-94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10-20%, but fully maintained against severe COVID-19.

引用

页数：10

共 50 条

[1] Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis
Mahumud, Rashidul Alam
Ali, Mohammad Afshar
Kundu, Satyajit
Rahman, Md Ashfikur
Kamara, Joseph Kihika
Renzaho, Andre M. N.
VACCINES, 2022, 10 (02)
[2] Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies
Pormohammad, Ali
Zarei, Mohammad
Ghorbani, Saied
Mohammadi, Mehdi
Neshin, Saeideh Aghayari Sheikh
Khatami, Alireza
Turner, Diana L.
Djalalinia, Shirin
Mousavi, Seied Asadollah
Mardani-Fard, Heydar Ali
Kasaeian, Amir
Turner, Raymond J.
VACCINES, 2022, 10 (01)
[3] Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021
Harderi, Thomas
Kochi, Judith
Vygen-Bonneti, Sabine
Kuelper-Schieki, Wiebe
Pilici, Antonia
Redai, Sarah
Scholzi, Stefan
Wichmann, Ole
EUROSURVEILLANCE, 2021, 26 (28)
[4] Histopathological Lung Findings in COVID-19 B.1.617.2 SARS-CoV-2 Delta Variant
Jeican, Ionut Isaia
Inisca, Patricia
Gheban, Dan
Anton, Vlad
Lazar, Mihaela
Vica, Mihaela Laura
Mironescu, Daniela
Rebeleanu, Codrin
Crivii, Carmen Bianca
Aluas, Maria
Albu, Silviu
Siserman, Costel Vasile
JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (02):
[5] Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (vol 385, pg 585, 2021)
不详
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (07): : 672 - 672
[6] Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic
Tareq, Abu Montakim
Emran, Talha Bin
Dhama, Kuldeep
Dhawan, Manish
Tallei, Trina Ekawati
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (11) : 4126 - 4127
[7] Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
Wang, Stephen Y.
Juthani, Prerak, V
Borges, Kelly A.
Shallow, Marcus K.
Gupta, Akash
Price, Christina
Won, Christine H.
Chun, Hyung J.
LANCET MICROBE, 2022, 3 (01): : E4 - E5
[8] Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
Zeng, Baoqi
Gao, Le
Zhou, Qingxin
Yu, Kai
Sun, Feng
BMC MEDICINE, 2022, 20 (01)
[9] Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
Baoqi Zeng
Le Gao
Qingxin Zhou
Kai Yu
Feng Sun
BMC Medicine, 20
[10] Guangdong's Study of the Effectiveness of China's Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant
Wang, Fuzhen
An, Zhijie
Rodewald, Lance
Wu, Dan
Tang, Lin
Zheng, Hui
Liu, Qianqian
Gao, George F.
Yin, Zundong
CHINA CDC WEEKLY, 2021, 3 (34): : 728 - 730

← 1 2 3 4 5 →